Phillips-Medisize, Dance Biopharm ink deal for inhaled insulin device

Share

Phillips-MedisizePrivately-held biotech Dance Biopharm and Phillips-Medisize have entered into a joint development deal for a connected drug-delivery device for inhaled insulin.

The agreement gives Phillips-Medisize, which already designs and manufactures devices for Dance, the development work for future enhancements of Dance’s devices, as well as commercial manufacturing of the inhaled insulin delivery device when it gets to the market.

The Dance 501 device stores a liquid formulation of recombinant human insulin in a dispenser with a hand-held electronic inhaler. The device uses vibrating mesh to produce particles of liquid insulin in a soft mist.

Get the full story on our sister site Drug Delivery Business News.

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*